Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
AstraZeneca Licenses Vanderbilt Compounds
by Lisa M. Jarvis
January 21, 2013
| A version of this story appeared in
Volume 91, Issue 3
AstraZeneca has teamed with the Vanderbilt Center for Neuroscience Drug Discovery to discover drugs to treat psychosis associated with major brain diseases. AstraZeneca has paid VCNDD an undisclosed sum for the rights to small molecules that act on the M4 muscarinic acetylcholine receptor; the firm will also chip in two years of research funding for the development of those and newer M4 compounds. The deal with AstraZeneca is the latest tie-up for VCNDD and a major drug firm. In September, Bristol-Myers Squibb licensed allosteric modulators of the mGluR4 glutamate receptor from VCNDD.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter